Currently, there are 259.96M common shares owned by the public and among those 259.00M shares have been available to trade.
The company’s stock has a 5-day price change of 3.79% and -42.71% over the past three months. OGN shares are trading -41.29% year to date (YTD), with the 12-month market performance down to -59.29% lower. It has a 12-month low price of $8.01 and touched a high of $23.10 over the same period. OGN has an average intraday trading volume of 5.49 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -11.85%, -28.01%, and -45.05% respectively.
Institutional ownership of Organon & Co (NYSE: OGN) shares accounts for 80.42% of the company’s 259.96M shares outstanding.
It has a market capitalization of $2.28B and a beta (3y monthly) value of 0.51. The stock’s trailing 12-month PE ratio is 3.03, while the earnings-per-share (ttm) stands at $2.89. The company has a PEG of 20.22 and a Quick Ratio of 1.15 with the debt-to-equity ratio at 16.52. Price movements for the stock have been influenced by the stock’s volatility, which stands at 6.09% over the week and 6.81% over the month.
Earnings per share for the fiscal year are expected to decrease by -5.24%, and 3.59% over the next financial year. EPS should grow at an annualized rate of 0.15% over the next five years, compared to -23.49% over the past 5-year period.
JP Morgan coverage for the Organon & Co (OGN) stock in a research note released on September 06, 2024 offered a Underweight rating with a price target of $20. Goldman was of a view on November 03, 2023 that the stock is Neutral, while Barclays gave the stock Overweight rating on September 21, 2023, issuing a price target of $28. Raymond James on their part issued Outperform rating on March 16, 2023.
